Proteasome Inhibitor
BLd Combination Therapy for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
Anti-metabolites
Azacitidine +/− Lenalidomide/Vorinostat for Higher-Risk MDS/CMML
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Popular Filters
Phase 3 Trials
Immunomodulatory Agent
Lenalidomide for Smoldering Multiple Myeloma
Recruiting4 awardsPhase 3
Anchorage, Alaska
This trial compares lenalidomide to observation in treating patients with asymptomatic high-risk multiple myeloma. It is not yet known whether lenalidomide is more effective than observation alone.
Alkylating agents
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Corticosteroid
Lenalidomide + Dexamethasone +/- Thalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial tests if lenalidomide with either standard or low-dose dexamethasone works better for new multiple myeloma patients. If not, thalidomide is added. The goal is to find effective treatments with fewer side effects. Lenalidomide plus low-dose dexamethasone has been shown to be an effective treatment for multiple myeloma, particularly in patients who are not candidates for stem cell transplantation.
Trials With No Placebo
Immunomodulatory Agent
Lenalidomide for Smoldering Multiple Myeloma
Recruiting4 awardsPhase 3
Anchorage, Alaska
This trial compares lenalidomide to observation in treating patients with asymptomatic high-risk multiple myeloma. It is not yet known whether lenalidomide is more effective than observation alone.
Alkylating agents
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.